



Media Contacts: BioGenerator - Colleen Ward, 314.880.8873, cward@biostl.org
Cultivation Capital - Kelly Grote, 314.972.3676, kgrote@cultivationcapital.com

Cultivation Capital, BioGenerator, and St. Louis Arch Angels Announce Investment in Euclises

ST. LOUIS – April 7, 2015 – Venture capital firm Cultivation Capital, St. Louis Arch Angels, and [BioGenerator](#), an evergreen investor that creates, grows and invests in promising companies and entrepreneurs, announce the funding of Euclises Pharmaceuticals, Inc., a biotechnology company developing novel COX-2 inhibitors for the treatment of cancer. The funding is part of a nearly \$2 million round.

Euclises, located in the BioGenerator Labs, has developed a portfolio of third-generation COX-2 inhibitors optimized for cancer treatment based on its proprietary Euclicoxib™ platform and is advancing its lead clinical development candidate to the IND stage. In conjunction with its development partnership with Guangzhou Institutes of Biomedicine and Health (GIBH), Euclises expects these additional monies to enable the company to complete its ongoing preclinical studies and to file an IND for human clinical trials in cancer patients in 2016.

“BioGenerator’s post-seed funding represents our third investment in Euclises,” said Charlie Bolten, vice president of BioGenerator. “Euclises has made great progress with a strong leadership team of CSO Dr. John Talley and new CEO Dr. Bobby W. Sandage, Jr., along with a unique agreement with GIBH. As the initial investor in the company, we recognize Euclises’ unique approach to cancer treatment and the potential in the technology.”

With the additions to the leadership team, Euclises is continuing its work to unlock the power of clinically proven COX-2 inhibitors in cancer by collaborating with GIBH to conduct preclinical development de-risking activities at a reduced R&D cost. Euclises continues to build on its success with its newest developments.

“Euclises’ relationship with GIBH and the new addition of a veteran Pharma CEO provide strong validation and positioning for the company’s future. This marks Cultivation Capital’s second investment in Euclises,” stated Dr. Rick Ryan, general partner of Cultivation Capital and Euclises board member. “The relationship with GIBH will enable Euclises to do the IND enabling studies with an extremely capital efficient plan.”

“The St. Louis Arch Angels is pleased to make its fourth investment in Euclises. Our participation demonstrates our continued confidence in the management team and progress shown by the company,” said Dr. Robert Calcaterra, president of the St. Louis Arch Angels.

About Cultivation Capital

Cultivation Capital is a St. Louis-based early stage Venture Capital firm investing in high potential technology companies throughout the Midwest. Cultivation Capital is managed by a team of experienced entrepreneurs, who have started more than 25 companies, raised more than \$200 Million dollars and had several successful exits. For more information, visit <http://www.cultivationcapital.com>.

About BioGenerator

BioGenerator produces a sustained pipeline of successful bioscience companies and entrepreneurs in St. Louis by creating, growing and investing in promising new enterprises. BioGenerator is a nonprofit subsidiary of BioSTL, which advances St. Louis' prosperity by cultivating a thriving bioscience sector, building regional capacity to capitalize on St. Louis' world class medical and plant biosciences. Please visit www.BioGenerator.org for additional information. Follow BioGenerator on Twitter [@BioGeneratorSTL](https://twitter.com/BioGeneratorSTL).

About St. Louis Arch Angels

The St. Louis Arch Angels is an angel investment network of 85 members who have invested well over \$50M in approximately 60 companies since its inception in 2005. Investments have been primarily in the agricultural, life sciences and IT areas. The organization meets on a regular monthly basis, has looked at well over 500 deals in its 10 year existence and has invested as little as \$200,000 and as high as \$6M in individual companies. The network has had approximately 6 exits and only a few company failures to date.

###